17β-Estradiol Improves Survival in Male Mice with Cardiomyopathy Induced by Cardiac-Specific Tumor Necrosis Factor-α Overexpression

A transgenic mouse model of congestive heart failure (CHF) consequent to cardiac-specific overexpression of tumor necrosis factor-α (TNF-α) (TNF1.6) displays marked sex-related phenotypic differenc...

[1]  C. Chassagne,et al.  Expression of laminin α2 chain during normal and pathological growth of myocardium in rat and human , 2000 .

[2]  Y. Ouchi,et al.  17 beta-estradiol inhibits cardiac fibroblast growth through both subtypes of estrogen receptor. , 2003, Biochemical and biophysical research communications.

[3]  G. Koch,et al.  Gender differences in survival in advanced heart failure. Insights from the FIRST study. , 1999, Circulation.

[4]  J. Isner,et al.  Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. , 1997, Circulation.

[5]  B. McGowan,et al.  Tumor Necrosis Factor Receptors 1 and 2 Differentially Regulate Survival, Cardiac Dysfunction, and Remodeling in Transgenic Mice With Tumor Necrosis Factor-&agr;–Induced Cardiomyopathy , 2004 .

[6]  P. Doevendans,et al.  17&bgr;-Estradiol Antagonizes Cardiomyocyte Hypertrophy by Autocrine/Paracrine Stimulation of a Guanylyl Cyclase A Receptor-Cyclic Guanosine Monophosphate-Dependent Protein Kinase Pathway , 2004 .

[7]  J. Guerrero,et al.  Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. , 1999, The Journal of clinical investigation.

[8]  K. Kikuchi,et al.  cAMP-mediated c-fos expression in pressure-overloaded acceleration of protein synthesis in adult rat heart. , 1997, Cardiovascular research.

[9]  A. M. Cabral,et al.  Sex Hormone Modulation of Ventricular Hypertrophy in Sinoaortic Denervated Rats , 1988, Hypertension.

[10]  A. Feldman,et al.  Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. , 2000, The Journal of clinical investigation.

[11]  E. Vittinghoff,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[12]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[13]  F. Ross,et al.  Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. , 1999, The Journal of clinical investigation.

[14]  Y. Fujio,et al.  Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. , 1997, The Journal of clinical investigation.

[15]  R. Virmani,et al.  Myocardial protection of contractile function after global ischemia by physiologic estrogen replacement in the ovariectomized rat. , 1997, Journal of molecular and cellular cardiology.

[16]  A. Kimchi,et al.  Cathepsin D protease mediates programmed cell death induced by interferon‐gamma, Fas/APO‐1 and TNF‐alpha. , 1996, The EMBO journal.

[17]  S. Sankey,et al.  Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. , 2003, American journal of physiology. Heart and circulatory physiology.

[18]  C. Yancy,et al.  Hormone replacement therapy is associated with improved survival in women with advanced heart failure. , 2003, Journal of the American College of Cardiology.

[19]  H. S. Choi,et al.  Estrogen receptor, a common interaction partner for a subset of nuclear receptors. , 1998, Molecular endocrinology.

[20]  Simon C Watkins,et al.  Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Reis,et al.  Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. , 2000, Journal of the American College of Cardiology.

[22]  A. D'ercole,et al.  Ontogeny of somatomedin during development in the mouse. Serum concentrations, molecular forms, binding proteins, and tissue receptors. , 1980, Developmental biology.

[23]  A. Takeshita,et al.  Disruption of Inducible Nitric Oxide Synthase Improves &bgr;-Adrenergic Inotropic Responsiveness but Not the Survival of Mice With Cytokine-Induced Cardiomyopathy , 2002, Circulation research.

[24]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[25]  P. Georgiades,et al.  REGULATION OF RETINOID X RECEPTOR‐γ GENE TRANSCRIPT LEVELS IN RAT HEART CELLS , 1998 .

[26]  R. Peshock,et al.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.

[27]  J. Gustafsson,et al.  Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Robbins,et al.  Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. , 2000, Circulation.

[29]  R. Karas,et al.  Cardiac myocytes and fibroblasts contain functional estrogen receptors 1 , 1997, FEBS letters.

[30]  M. Mendelsohn,et al.  Protective effects of estrogen on the cardiovascular system. , 1999, The American journal of cardiology.

[31]  L. Liotta,et al.  Modulation of laminin receptor expression by estrogen and progestins in human breast cancer cell lines. , 1988, Journal of the National Cancer Institute.